Name of study:
A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat with Pembro and CTX Versus Placebo with Pembro and CTX in 1L, Metastatic KEAP1/NRF2-Mutated, Nonsquamous NSCLC
Purpose of study:
This is a randomized Phase 2 study that will test whether the investigational study drug called telaglenastat will be safe and potentially effective when combined with the FDA approved immunochemotherapy regimen of pembrolizumab, carboplatin, and pemetrexed in treating patients with stage IV lung cancer that has a mutation in NRF2/(NFE2L2) or KEAP1 genes. Patients on this study will not have received any systemic treatment for advanced lung cancer. All patients in this study will receive the approved recommended treatment regimen of pembrolizumab, carboplatin, and pemetrexed either with or without telaglenastat.
Is this a pre- or post- market study?:
Is the study of a controlled or observational design?
What is the funding source?:
Where is the study being conducted?
Multiple Sites located in the U.S.
City and State:
When the study is being conducted:
Start Date: 2/1/2020
What website should a person use to register for the study?
None - Advise to speak to your physician regarding this trial
Who should a person contact to register for the study?
Who is sponsoring this study?
What is the identifier for this study on ClinicalTrials.gov?
Page last updated: February 23, 2021